Edition:
United States

People: OncoMed Pharmaceuticals Inc (OMED.OQ)

OMED.OQ on NASDAQ Stock Exchange Global Select Market

1.93USD
1:29pm EDT
Change (% chg)

$-0.06 (-3.02%)
Prev Close
$1.99
Open
$1.92
Day's High
$1.93
Day's Low
$1.89
Volume
8,035
Avg. Vol
11,841
52-wk High
$5.55
52-wk Low
$1.75

Pakianathan, Deepika 

Dr. Deepa R. Pakianathan is Independent Director of OncoMed Pharmaceuticals, Inc. Since 2001, Dr. Pakianathan has been a Managing Member at Delphi Ventures, a venture capital firm focused on medical device and biotechnology investments, and leads the firm’s biotechnology investment activities. Prior to joining Delphi Ventures, she served as a Vice President in the healthcare group of JP Morgan. Since 2004, Dr. Pakianathan has served on the board of directors of Alexza Pharmaceuticals, Inc., a publicly traded pharmaceutical company, where she also serves as a member of its audit committee and corporate governance and nominating committee. Since December 2007, Dr. Pakianathan has served on the board of directors of Alder Biopharmaceuticals, Inc., a publicly traded pharmaceutical company, where she also serves as a member of its governance and nominating committee. Since September 2012, Dr. Pakianathan has served on the board of directors of Calithera Biosciences, Inc., a publicly traded pharmaceutical company. Since April 2013, Dr. Pakianathan has served on the board of directors of Kayropharm Therapeutics, Inc., a publicly traded pharmaceutical company. Dr. Pakianathan previously served on the boards of directors of PTC Therapeutics, Inc. and Relypsa, Inc., each a publicly traded pharmaceutical company. Dr. Pakianathan received a B.Sc from the University of Bombay, India, a M.Sc from The Cancer Research Institute at the University of Bombay, India, and an M.S. and Ph.D. from Wake Forest University.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --